| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/46.5.775 |
| P698 | PubMed publication ID | 11062197 |
| P2093 | author name string | Talbot GH | |
| Perfect JR | |||
| Drew RH | |||
| Srinath L | |||
| Dowzicky M | |||
| Kurkimilis E | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| Staphylococcus aureus | Q188121 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 775-784 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. | |
| P478 | volume | 46 |
| Q53854341 | Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis. |
| Q38783509 | An update on drug-induced arthritis |
| Q43237184 | Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections? |
| Q36514161 | Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment |
| Q36968150 | Antimicrobial therapy of Staphylococcus aureus bloodstream infection |
| Q43999843 | Clinical experience of quinupristin-dalfopristin for the treatment of antimicrobial-resistant gram-positive infections |
| Q34441035 | Clinical management of Staphylococcus aureus bacteremia: a review |
| Q38099554 | Clinical management of septic arthritis |
| Q35684359 | Clinical pharmacokinetics of quinupristin/dalfopristin |
| Q34157657 | Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children |
| Q51195354 | Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus. |
| Q81323174 | Community-associated methicillin-resistant Staphylococcus aureus: incidence, clinical presentation, and treatment decisions |
| Q37465197 | Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management |
| Q26853465 | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci |
| Q36233506 | Current use of anti-infectives in dermatology |
| Q37853607 | Cutaneous community-acquired and hospital-acquired methicillin-resistant Staphylococcus aureus |
| Q37319460 | Daptomycin in bone and joint infections: a review of the literature |
| Q46456918 | Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis |
| Q38907793 | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). |
| Q43237186 | Early appropriate therapy of Gram-positive bloodstream infections: the conservative use of new drugs |
| Q36718474 | Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections |
| Q37850450 | From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems |
| Q53879693 | Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. |
| Q36409465 | Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. |
| Q34589960 | Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit |
| Q39731843 | In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci |
| Q50791170 | Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms. |
| Q38995472 | Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults |
| Q36025384 | Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. |
| Q37156709 | Management of methicillin-resistant Staphylococcus aureus bacteremia |
| Q80585586 | Medical treatment of endocarditis |
| Q35026548 | Methicillin-resistant Staphylococcus aureus in HIV-infected patients |
| Q27011165 | Methicillin-resistant Staphylococcus aureus therapy: past, present, and future |
| Q33251997 | Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. |
| Q37636913 | New antibiotics: optimal use in current clinical practice |
| Q36953330 | New antimicrobial agents as therapy for resistant gram-positive cocci |
| Q35838370 | Newer treatment options for skin and soft tissue infections |
| Q39616901 | Novel systemic antibiotics in dermatology |
| Q91832344 | Occurrence of multidrug-resistant methicillin-resistant Staphylococcus aureus among healthy farm animals: a public health concern |
| Q38541963 | Periprosthetic joint infection |
| Q45127594 | Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections |
| Q43767544 | Problems and current solutions for the treatment of infections caused by gram-positive microorganisms |
| Q34783668 | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q34187667 | Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole |
| Q35066795 | Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy |
| Q37058032 | Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection |
| Q34715626 | Special issues in the management of infective endocarditis caused by gram-positive cocci |
| Q36894458 | Staphylococci. |
| Q73697469 | Staphylococcus aureus bacteremia and endocarditis |
| Q74393437 | Staphylococcus aureus bacteremia and endocarditis |
| Q43197982 | Successful medical treatment of bioprosthetic pulmonary valve endocarditis caused by methicillin-resistant Staphylococcus aureus |
| Q44958662 | The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus |
| Q40667218 | The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper |
| Q36697683 | The use of systemic antibiotics in the treatment of chronic wounds |
| Q36758570 | Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions |
Search more.